Mylan, Inc, announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc, under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide as both a single agent product and in combination with other drugs.
Study finds that HIV drug regimens that exclude efavirenz are as effective as first-line antiretroviral treatment.
Beginning therapy within 12 months of HIV detection associated with lower AIDS risk.
Of the 1.2 million Americans with human immunodeficiency virus in 2011, 70% did not have their condition under control.
Study finds treatment that prevents transmission of virus from mother to child leads to reduced heart performance.
Three-drug regimen will lead to new treatment protocols for transplant patients, study finds.
A study from Merck has demonstrated high response to grazoprevir/elbasvir with and without ribavirin across various hepatitis C virus populations, including difficult-to-cure patients.
A trio of studies from AbbVie provides good news for patients with hepatitis C virus, including those with comorbid HIV or cirrhosis.
Women may need more frequent ART doses to prevent HIV transmission than men, a mathematical model suggests
If approved, it would be Gilead's first single-tablet HIV regimen to contain TAF.
Gilead Sciences, Inc., has submitted a new drug application to the FDA for its investigational single-tablet regimen for HIV infection in adult patients.
Following completion of phase 2 trial, phase 3 enrollment expected to start by end of the year.
An investigational HIV drug developed by Merck exhibited a strong overall safety and efficacy profile in a recently completed phase 2b study.
Discovery offers potential target for future HIV treatments.
Could the key to fighting modern illnesses lie in a disease that was an epidemic centuries ago?
Researchers identify mechanisms that trigger hematopoietic stem cell production.
Antiretroviral therapy provides similar benefits for stimulant users and non-users alike.
The vaccine that prevents illness and death from pneumococcal infection also combats severe antibiotic-resistant disease in young children.
Provides use, cost forecast based on testing, future treatment rates.
Harvoni is comprised of sofosbuvir, a previously approved HCV drug marketed under the brand name Sovaldi, and a new drug called ledipasvir.
Tobacco users have an increased risk of oral human papillomavirus type 16, a sexually transmitted virus that is strongly associated with cervical cancer.
Virus was undetectable for 3 years before researchers discovered viral reservoirs have not disappeared.
Parents who know about the human papillomavirus are not more likely to get their adolescent daughters vaccinated.
Findings of study provide new options for future vaccine development.
